A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
This observational or N/A phase trial investigates Advanced Cervical Cancer and is currently actively recruiting participants. Shanghai Shengdi Pharmaceutical Co., Ltd leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
3 versions recorded-
Apr 16, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Dec 2025 — Apr 2026 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2025 — Dec 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Contact Information
- Shanghai Shengdi Pharmaceutical Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .